Skip to main content
Top
Published in: International Urology and Nephrology 4/2018

01-04-2018 | Urology - Original Paper

Outcomes of synchronous and metachronous bilateral small renal masses (< 4 cm): a population-based cohort study

Authors: Nissar Ahmed Sheikh, Mohammed Hassan Khan, Sanjay Pillai, Stephen Lang, Ghulam Nabi

Published in: International Urology and Nephrology | Issue 4/2018

Login to get access

Abstract

Objectives

To report longitudinal outcomes of a population-based cohort of patients diagnosed with bilateral small renal masses from a period of over 11 years.

Patients and methods

Consecutive patients diagnosed with bilateral small renal masses (synchronous or metachronous) of a defined geographical area were recorded in a large database (TUCAN database) between January 2005 and December 2016. Patients had a unique identifier number and followed during this period using an agreed upon protocol. Clinicopathological characteristics and outcomes of bilateral small renal masses on active surveillance were analysed and compared to propensity score-matched sporadic unilateral small renal masses. Data were analysed for renal mass growth rate, rate of intervention and development of metastatic disease and patient survival.

Results

A total of 1060 patients were diagnosed with renal cancer, of which bilateral small renal masses accounted for 70 (6.6%) cases. Synchronous SRMs were observed in 63 patients, whereas metachronous lesions were found in seven patients during the study period. Metachronous lesion mean time to appearance was 62 ± 41 months (range 9–149 months). While most cases were sporadic, four were found to be hereditary. Growth rate of bilateral small renal masses did not differ from that of unilateral sporadic small renal masses. Similarly, there were no differences between the groups for rate of interventions and survival.

Conclusions

Progression, rate of metastases and survival for patients diagnosed with bilateral small renal masses are similar to those diagnosed with unilateral disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hu XY et al (2017) Surgical strategy of bilateral synchronous sporadic renal cell carcinoma—experience of a Chinese University Hospital. World J Surg Oncol 15(1):53CrossRefPubMedPubMedCentral Hu XY et al (2017) Surgical strategy of bilateral synchronous sporadic renal cell carcinoma—experience of a Chinese University Hospital. World J Surg Oncol 15(1):53CrossRefPubMedPubMedCentral
2.
go back to reference Berczi C et al (2016) Bilateral renal cancers: oncological and functional outcomes. Int Urol Nephrol 48(10):1617–1622CrossRefPubMed Berczi C et al (2016) Bilateral renal cancers: oncological and functional outcomes. Int Urol Nephrol 48(10):1617–1622CrossRefPubMed
3.
go back to reference Wells GM et al (2009) Bilateral renal-cell carcinoma associated with an acquired VHL mutation and long-term trichloroethylene exposure. Clin Nephrol 71(6):708–713CrossRefPubMed Wells GM et al (2009) Bilateral renal-cell carcinoma associated with an acquired VHL mutation and long-term trichloroethylene exposure. Clin Nephrol 71(6):708–713CrossRefPubMed
4.
go back to reference Jacobs SC, Berg SI, Lawson RK (1980) Synchronous bilateral renal cell carcinoma: total surgical excision. Cancer 46(11):2341–2345CrossRefPubMed Jacobs SC, Berg SI, Lawson RK (1980) Synchronous bilateral renal cell carcinoma: total surgical excision. Cancer 46(11):2341–2345CrossRefPubMed
5.
go back to reference Yu CC et al (1992) Simultaneous bilateral adrenal metastases from renal cell carcinoma. Surgical implications and review of the literature. Eur Urol 22(4):335–338CrossRefPubMed Yu CC et al (1992) Simultaneous bilateral adrenal metastases from renal cell carcinoma. Surgical implications and review of the literature. Eur Urol 22(4):335–338CrossRefPubMed
6.
go back to reference Tracy CR et al (2010) Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. Cancer 116(13):3135–3142CrossRefPubMed Tracy CR et al (2010) Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. Cancer 116(13):3135–3142CrossRefPubMed
7.
go back to reference Hollingsworth JM et al (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98(18):1331–1334CrossRefPubMed Hollingsworth JM et al (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98(18):1331–1334CrossRefPubMed
8.
go back to reference Wang B et al (2016) Bilateral synchronous sporadic renal cell carcinoma: retroperitoneoscopic strategies and intermediate outcomes of 60 patients. PLoS ONE 11(5):e0154578CrossRefPubMedPubMedCentral Wang B et al (2016) Bilateral synchronous sporadic renal cell carcinoma: retroperitoneoscopic strategies and intermediate outcomes of 60 patients. PLoS ONE 11(5):e0154578CrossRefPubMedPubMedCentral
9.
go back to reference Qi N et al (2017) Clinicopathologic features and prognosis of sporadic bilateral renal cell carcinoma: a series of 148 cases. Clin Genitourin Cancer 15(5):618–624CrossRefPubMed Qi N et al (2017) Clinicopathologic features and prognosis of sporadic bilateral renal cell carcinoma: a series of 148 cases. Clin Genitourin Cancer 15(5):618–624CrossRefPubMed
10.
go back to reference Pahernik S et al (2007) Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes. BJU Int 100(1):26–29CrossRefPubMed Pahernik S et al (2007) Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes. BJU Int 100(1):26–29CrossRefPubMed
11.
go back to reference Jacobs BL et al (2009) Management of bilateral synchronous renal cell carcinoma in a single versus staged procedure. Can J Urol 16(1):4507–4511PubMed Jacobs BL et al (2009) Management of bilateral synchronous renal cell carcinoma in a single versus staged procedure. Can J Urol 16(1):4507–4511PubMed
12.
13.
go back to reference Leonard M et al (2013) Impact of multiple deprivations on detection, progression and interventions in small renal masses (less than 4 cm) in a population based study. Eur J Surg Oncol 39(10):1157–1163CrossRefPubMed Leonard M et al (2013) Impact of multiple deprivations on detection, progression and interventions in small renal masses (less than 4 cm) in a population based study. Eur J Surg Oncol 39(10):1157–1163CrossRefPubMed
14.
go back to reference Ganeswaran D et al (2014) Population-based linkage of health records to detect urological complications and hospitalisation following transrectal ultrasound-guided biopsies in men suspected of prostate cancer. World J Urol 32(2):309–315CrossRefPubMed Ganeswaran D et al (2014) Population-based linkage of health records to detect urological complications and hospitalisation following transrectal ultrasound-guided biopsies in men suspected of prostate cancer. World J Urol 32(2):309–315CrossRefPubMed
15.
go back to reference Paterson C et al (2017) Predictors of growth kinetics and outcomes in small renal masses (SRM ≤ 4 cm in size): Tayside Active Surveillance Cohort (TASC) Study. Eur J Surg Oncol 43:1589–1597CrossRefPubMed Paterson C et al (2017) Predictors of growth kinetics and outcomes in small renal masses (SRM ≤ 4 cm in size): Tayside Active Surveillance Cohort (TASC) Study. Eur J Surg Oncol 43:1589–1597CrossRefPubMed
16.
go back to reference Haas NB, Nathanson KL (2014) Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis 21(1):81–90CrossRefPubMed Haas NB, Nathanson KL (2014) Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis 21(1):81–90CrossRefPubMed
17.
go back to reference Rednam SP et al (2017) Von Hippel–Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23(12):e68–e75CrossRefPubMed Rednam SP et al (2017) Von Hippel–Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 23(12):e68–e75CrossRefPubMed
18.
go back to reference Walther MM et al (1999) Clinical and genetic characterization of pheochromocytoma in von Hippel–Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162(3 Pt 1):659–664CrossRefPubMed Walther MM et al (1999) Clinical and genetic characterization of pheochromocytoma in von Hippel–Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162(3 Pt 1):659–664CrossRefPubMed
19.
go back to reference Blute ML et al (2003) The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol 169(4):1276–1281CrossRefPubMed Blute ML et al (2003) The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol 169(4):1276–1281CrossRefPubMed
20.
go back to reference Paterson C et al (2017) Predictors of growth kinetics and outcomes in small renal masses (SRM ≤ 4 cm in size): Tayside Active Surveillance Cohort (TASC) Study. Eur J Surg Oncol 43(8):1589–1597CrossRefPubMed Paterson C et al (2017) Predictors of growth kinetics and outcomes in small renal masses (SRM ≤ 4 cm in size): Tayside Active Surveillance Cohort (TASC) Study. Eur J Surg Oncol 43(8):1589–1597CrossRefPubMed
21.
go back to reference Klatte T et al (2007) Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol 177(6):2081–2086 (discussion 2086-7) CrossRefPubMed Klatte T et al (2007) Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol 177(6):2081–2086 (discussion 2086-7) CrossRefPubMed
22.
go back to reference Kume H, Teramoto S, Kitamura T (2009) Metachronous bilateral renal cell carcinoma with an interval of more than 10 years. Int Urol Nephrol 41(4):843–846CrossRefPubMed Kume H, Teramoto S, Kitamura T (2009) Metachronous bilateral renal cell carcinoma with an interval of more than 10 years. Int Urol Nephrol 41(4):843–846CrossRefPubMed
23.
go back to reference Boorjian SA et al (2008) The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol 54(4):855–863CrossRefPubMed Boorjian SA et al (2008) The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol 54(4):855–863CrossRefPubMed
24.
go back to reference Canter D et al (2011) Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology 78(5):1089–1094CrossRefPubMedPubMedCentral Canter D et al (2011) Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. Urology 78(5):1089–1094CrossRefPubMedPubMedCentral
25.
go back to reference Yoshida K et al (2016) Comparison of diameter-axial-polar nephrometry score and RENAL nephrometry score for surgical outcomes following laparoscopic partial nephrectomy. Int J Urol 23(2):148–152CrossRefPubMed Yoshida K et al (2016) Comparison of diameter-axial-polar nephrometry score and RENAL nephrometry score for surgical outcomes following laparoscopic partial nephrectomy. Int J Urol 23(2):148–152CrossRefPubMed
Metadata
Title
Outcomes of synchronous and metachronous bilateral small renal masses (< 4 cm): a population-based cohort study
Authors
Nissar Ahmed Sheikh
Mohammed Hassan Khan
Sanjay Pillai
Stephen Lang
Ghulam Nabi
Publication date
01-04-2018
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-1817-x

Other articles of this Issue 4/2018

International Urology and Nephrology 4/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.